Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services
FDA, U.S. Food and Drug Administration
U.S. Food & Drug Administration
 
  • A to Z Index
  • Follow FDA
  • FDA Voice Blog
Search
 
Most Popular Searches
 
  • Home
  • Food
  • Drugs
  • Medical Devices
  • Vaccines, Blood & Biologics
  • Animal & Veterinary
  • Cosmetics
  • Radiation-Emitting Products
  • Tobacco Products
 

Import Alert 66-60

  • Print
  • Share
  • E-mail
  • FDA Home
  • Import Program
  • Import Alerts
  • Imports Alerts by Number
  • Import Alert
-

(Note: This import alert represents the Agency's current guidance to FDA field personnel regarding the manufacturer(s) and/or products(s) at issue. It does not create or confer any rights for or on any person, and does not operate to bind FDA or the public).

Import Alert # 66-60
Published Date: 03/18/2011
Type: DWPE
Import Alert Name:
"Detention Without Physical Eamaintion of Certain Steroid Alternatives"

Reason for Alert:
Unapproved alternatives to anabolic steroids have commonly been found to present serious safety and effectiveness concerns. In February, 1991, anabolic steroids became controlled substances. This is one factor which has stimulated the market for imported steroid alternatives.

Guidance:
Districts may detain without physical examination all shipments of finished dosage forms (both commercial and personal) of the cited unapproved products. Do not collect samples for laboratory analysis. Districts should determine whether the drugs are covered by a current approved NDA or IND. Those products covered by an approved NDA or IND should be released.

Bulk forms of these drugs may be detained under certain circumstances as misbranded drugs; however, prior to initiating any action against bulk pharmaceutical chemicals, contact CDER's Import/Export Branch.

Product Description:
Foreign manufactured unapproved drugs promoted as alternatives to certain anabolic steroids i.e.,

* Yohimbe Bark or Yohimbe Bark Extract
* Cyclofenil
* Gamma Hydroxybutyrate (GHB)
* Diosgenin
* Clenbuterol

Charge:
"The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved new drug application [Unapproved New Drug, Section 505(a)]."

OASIS Charge Code - UNAPPROVED

Countries

MULTIPLE COUNTRIES (PODS ONLY)
(60 D - - 99) Adrenocortical Steroid N.E.C.
Notes:Yohimbe Bark or Yohimbe Bark Extract Cyclofenil Gamma Hydroxybutyrate (GHB) Diosgenin Clenbuterol
-
-

Links on this page:

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.


  • Accessibility
  • Contact FDA
  • Careers
  • FDA Basics
  • FOIA
  • No Fear Act
  • Site Map
  • Transparency
  • Website Policies
FDA
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA
  • USA.gov
  • E-mail
  • RSS
  • Twitter
  • Facebook
  • YouTube
  • Flickr
  • For Government
  • For Press
  • Combination Products
  • Advisory Committees
  • Science & Research
  • Regulatory Information
  • Safety
  • Emergency Preparedness
  • International Programs
  • News & Events
  • Training and Continuing Education
  • Inspections/Compliance
  • State & Local Officials
  • Consumers
  • Industry
  • Health Professionals
U.S. Department of Health & Human Services
 

Links on this page: